SUPN - Company ID 0001356576
The table below shows SUPERNUS PHARMACEUTICALS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $207.71M | $192.10M | $165.45M | $149.82M | $175.69M | $168.32M |
| Cost of revenue | $23.39M | $18.96M | $16.83M | $15.76M | $17.58M | $17.92M |
| Gross profit | - | - | - | - | - | - |
| R&D | $39.44M | $29.37M | $22.11M | $26.93M | $29.04M | $26.18M |
SUPERNUS PHARMACEUTICALS, INC. reported annual revenue of $718.95M for fiscal year 2025. That is up 8.6% from $661.82M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $215.00M (FY 2016) to $718.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $125.17M |
| $179.68M |
| $93.55M |
| $89.94M |
| $69.75M |
| $85.90M |
| Operating income | -$8.33M | -$60.23M | $12.14M | -$10.26M | $40.84M | $22.57M |
| Income tax | -$3.66M | -$12.84M | -$5.83M | $6.00M | $6.45M | $6.39M |
| Net income | -$2.29M | -$45.12M | $22.50M | -$11.83M | $38.50M | $19.92M |
| EPS (diluted) | -$0.04 | -$0.80 | $0.40 | -$0.21 | $0.69 | $0.36 |